Vertex Pharmaceuticals Inc
F:VX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vertex Pharmaceuticals Inc
F:VX1
|
US |
|
Ingersoll Rand Inc
NYSE:IR
|
US |
|
Mediobanca Banca di Credito Finanziario SpA
MIL:MB
|
IT |
|
D
|
DBV Technologies SA
XMUN:DBV
|
FR |
Wall St Price Targets
VX1 Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for VX1 is 483.41 EUR with a low forecast of 287.27 EUR and a high forecast of 580.1 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is VX1's stock price target?
Price Target
483.41
EUR
According to Wall Street analysts, the average 1-year price target for VX1 is 483.41 EUR with a low forecast of 287.27 EUR and a high forecast of 580.1 EUR.
What is the Revenue forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.
What is the Gross Profit forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 8 years is 10%.
What is the Operating Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.
What is the Pre-Tax Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
20%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 47%. The projected CAGR for the next 3 years is 20%.
What is the Net Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
14%
The compound annual growth rate for Net Income over the next 8 years is 14%.
